At a scientific session of ACR Convergence 2025, Alexis Ogdie, MD, discussed new and forthcoming treatments for psoriatic arthritis.
Promising Combination Treatment for Gout
The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce serum uric acid levels in patients with uncontrolled gout.
FDA Approves 2 More Denosumab Biosimilars
The FDA as approved the biosimilar treatments denosumab-nxxp (Bildyos) and denosumab-nxxp (Bilprevda) for all indications of denosumab, their reference product, including osteoporosis in postmenopausal women.
Study: Are TNF Inhibitors Safe for Patients with RA-ILD?
Despite anecdotal reports to the contrary, a large observational study concludes that TNF inhibitors, compared with non-TNF biological or targeted synthetic DMARDs, do not cause higher rates of death or respiratory hospitalization in patients with RA-ILD.
Benefits of Early Initiation of Biologic DMARDs in pJIA
The early initiation of biologic disease-modifying anti-rheumatic drugs (DMARDs) may reduce the overall disease burden in patients with polyarticular juvenile idiopathic arthritis (pJIA), according to findings from Ringold et al.
Oral Treatment for PsA Inches Closer to FDA Approval
The FDA will consider a supplemental new drug application for deucravacitinib for the treatment of adults with active psoriatic arthritis based on promising results from clinical trials.
Rethinking Lupus Nephritis: Are Current Approaches & Guidelines off Target?
A rheumatologist & lupus expert reviews lupus nephritis treatment, questioning proteinuria cutoffs & ACR guidelines, advocating for newer therapies & end-of-treatment biopsies.
10 Things to Know about Lupus
SLE treatment is rapidly evolving as new therapies are developed & approved. Here are 10 key insights for clinicians.
Cardiovascular Risks Similar for JAK Inhibitors & bDMARDs
Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.
How the Experts Treat Sjögren’s Disease
With no FDA-approved drugs for Sjögren’s disease, experts share strategies for managing fatigue, arthritis, dryness, and systemic issues.
- 1
- 2
- 3
- …
- 43
- Next Page »